High-throughput screening in natural product drug discovery in Australia utilising Australia's biodiversity

Drug Development Research

Volumn 46, Issue 3-4, 1999, Pages 250-254

  Quinn, Ronald J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Australia; Biodiversity; High throughput screening; Natural products

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ACETYLSALICYLIC ACID; AMOXICILLIN; CAPTOPRIL; CLARITHROMYCIN; CLAVULANIC ACID; COMPACTIN; CYCLOSPORIN A; DEVAZEPIDE; ENALAPRIL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ARTICLE; BIODIVERSITY; DRUG ISOLATION; DRUG SCREENING; HERBAL MEDICINE; STRUCTURE ACTIVITY RELATION;

EID: 0033000738     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199903/04)46:3/4<250::AID-DDR9>3.0.CO;2-8     Document Type: Article

References (29)

1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirschfield J, Hoogsteen K, Liesch J, Springer J. 1980. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutyryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77:3957-3961.
2. Bock MG, Freidinger RM, Freedman SB, Matassa VG. 1995. Cholecystokinin (CCK) receptor antagonists. Curr Pharm Des 1:279-294.
3. 2-adrenoceptor. Nature 374:272-276.
4. Chang RSL, Lotti VJ. 1986. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 83:4923-4926.
5. Chang RSL, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schönberg G, Patchett AA, Liesch JM, Hensens OD, Springer JP. 1985. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science 230:177-179.
6. Cragg CM, Newman DJ, Snader KM. 1997. Natural products in drug discovery and development. J Nat Prod 60:52-60.
7. Dawson S, Henney A. 1992. The status of PAI-1 as a risk factor for arterial and thrombotic disease. Atherosclerosis 95:105-117.
8. Devlin JP. 1997a. Chemical diversity and genetic equity: synthetic and naturally derived compounds In: Devlin JP, editor. High throughput screening, the discovery of bioactive substances. New York: Marcel Dekker.
9. Devlin JP. 1997b. Microcollection of plants for biochemical screening. In: Devlin JP, editor. High throughput screening, the discovery of bioactive substances. New York: Marcel Dekker.
10. Endo A, Kuroda M, Tsujita Y. 1976. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot 29:1346-1348.
11. Evans BE, Bock MG. 1993. Promiscuity in receptor ligand research: benzodiazepine-based cholecystokinin antagonists. In: Maryanoff BE, Maryanoff CA, editors. Advances in medicinal chemistry, vol. 2. Greenwich, UK: JAI Press, p 111-152.
12. Evans BE, Bock MG, Ritter KE, DiPardo RM, Whitter WL, Veber DF, Anderson PS, Freidinger RM. 1986. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci USA 83:4918-4922.
13. 1 receptor for substance P and a non-peptide antagonist. Nature 362:345-348.
14. Haruyama H, Kuwano H, Kinoshita T, Terahara A, Nishigaki T, Tamura C. 1986. Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine. Chem Pharm Bull 34:1459-1467.
15. Harvey AL. 1993. An introduction to drugs from natural products. In: Harvey AL, editor. Drugs from natural products: pharmaceuticals and agrochemicals. Chichester: Ellis Horwood, p 1-6.
16. Hoffman WF, Alberts AW, Anderson PS, Chen JS, Smith RL, Willard AK. 1986. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. E. Side chain ester derivatives of mevinolin. J Med Chem 29:849-52.
17. Kathawala FG. 1991. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 11:121-146.
18. Krishnamurti C, Alving BM. 1992. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost 18:67-80.
19. Lowe JA III, McLean S. 1995. Tachykinin antagonists. Curr Pharm Des 1:269-278.
20. McNeely JA, Miller KR, Reid WV, Mittermeier RA, Werner TB. 1990. Conserving the world's biological diversity. Gland, Switzerland: IUCN.
21. Neve J, de Almeida Leone P, Carroll AR, Moni RW, Paczkowski NJ, Pierens G, Bjorquist P, Deinum J, Ehnebom J, Inghardt T, Guymer G, Grimshaw P, Quinn RJ. 1999. Sideroxylonal C. A new PAI-1 inhibitor from the flowers of Eucalyptus albens (Myrtaceae). J Nat Prod 62:324-326.
22. Petsko GA. 1996. For medicinal purposes. Nature 384:7-9.
23. Satoh H, Etoh H, Watanabe N, Kawagishi H, Arai K, Ina K. 1992. Structures of sideroxylonals from Eucalyptus sideroxylan. Chem Lett: 1917-1920.
24. Schwartz TW, Gether U, Schambye HT, Hjorth SA. 1995. Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr Pharm Des 1:325-342.
25. Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M Satoh M, Nishida A, Akusawa S, Miyata K. 1997. (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem 40:331-341.
26. Shu Y-Z. 1998. Recent natural products based drug development: a pharmaceutical industry perspective. J Nat Prod 61:1053-1071.
27. 1) receptor. Science 251:435-437.
28. Verstraete M, Collen D. 1986. Thrombolytic therapy in the eighties. Blood 67:1529-1541.
29. WCMC (World Conservation Monitoring Centre). 1992. Global biodiversity. Status of the earth's living resources. London: Chapman and Hall.